Answers are grounded in this paper and cite their sources.
Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by tremor, rigidity, bradykinesia, and postural instability, along with non-motor symptoms that can cause disability. Vitamin D, a fat-soluble secosteroid, influences gene expression by binding to the vitamin D receptor (VDR). It is essential for calcium homeostasis and metabolism and is also linked to various health conditions, including PD. In recent years, a high prevalence of vitamin D deficiency has been observed in PD patients. The enzymes converting vitamin D to its active form, VDR, and 1α-hydroxylase, are highly expressed in the substantia nigra. These findings indicate that low vitamin D levels may cause dysfunction or cell death in this brain region. Vitamin D impacts several biological processes in the central nervous system, including neurotransmission in dopaminergic circuits. Studies show lower vitamin D levels in Parkinson's patients compared to healthy controls. Links have been found between vitamin D levels and non-motor symptoms like mood disorders, orthostatic hypotension, and olfactory dysfunction, as well as motor severity. However, information on vitamin D's effects on non-motor symptoms is limited. This review seeks to critically examine the relationship between vitamin D and PD, focusing on the potential mechanisms through which vitamin D may influence the development, progression, and clinical management of PD. Additionally, it aims to evaluate the role of vitamin D in the prevention of PD and its therapeutic potential as an adjunctive treatment in patients with Parkinson’s disease.
No takes yet. Share an insight, caveat, or question.
AFACAN et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: